臨床検査56巻2号

2012年02月発行

今月の主題 生理活性脂質 各論

血小板活性化因子アセチルヒドロラーゼ

著者： 佐藤敬¹

所属機関： ¹弘前大学大学院医学研究科脳神経血管病態研究施設脳血管病態学講座

ページ範囲：P.151 - P.156

血小板活性化因子(PAF)を分解するPAFアセチルヒドロラーゼ(PAF-AH)は血漿リポ蛋白質と複合体を形成しており，脂質代謝異常，動脈硬化性疾患や炎症性疾患において高値となる．これについては様々な病態の結果であると考えられてきたが，その後，PAF-AHを疾患の危険因子とみなし，その阻害剤の第III相臨床試験も行われている．また，アジア人にみられるPAF-AH欠損症は，多くの報告では動脈硬化性疾患の遺伝的危険因子であることが示唆されているが，一部には全く反対の報告もみられ，血漿PAF-AHの臨床的意義は今後の研究成果に待つところが多いのが現状と言える．

参考文献

1) Imaizumi TA, Stafforini DM, Yamada Y, et al : Platelet-activating factor : a mediator for clinicians. J Intern Med　238：5-20，1995

2) Izumi T, Shimizu T : Platelet-activating factor receptor : gene expression and signal transduction. Biochim Biophys Acta　1295：317-333，1995

3) Snyder F, Fitzgerald V, Blank ML : Biosynthesis of platelet-activating factor and enzyme inhibitors. Adv Exp Med Biol　416：5-10，1996

4) Prescott SM, Zimmerman GA, Stafforini DM, et al : Platelet-activating factor and related lipid mediators. Annu Rev Biochem　69：419-445，2000

5) Stafforini DM, McIntyre TM, Zimmerman GA, et al : Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci　40：643-672，2003

6) Tjoelker LW, Wilder C, Eberhardt C, et al : Anti-inflammatory properties of a platelet-activating factor acetylhydrolase. Nature　374：549-553，1995

enzymes : classification and characterization. Biochim Biophys Acta　1488：1-19，2000

8) Stafforini DM, Tjoelker LW : Human plasma platelet-activating factor acetylhydrolase. Methods Mol Biol　109：49-58，1999

9) Smiley PL, Stremler KE, Prescott SM, et al : Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem　266：11104-11110，1991

10) Marathe GK, Prescott SM, Zimmerman GA, et al : Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med　11：139-142，2001

11) Stafforini DM, McIntyre TM, Carter ME, et al : Plasma platelet-activating factor acetylhydrolase : association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem　262：4215-4222，1987

12) Stafforini DM, Carter ME, Zimmerman GA, et al : Lipoproteins alter catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma. Proc Natl Acad Sci USA　86：2393-2397，1989

13) Pritchard PH, Chonn A, Yeung CC : The degradation of platelet-activating factor in the plasma of patient with familial high density lipoprotein deficiency (Tangier disease). Blood　66：1476-1478，1985

14) Ostermann G, Lang A, Holtz H, et al : The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. Thromb Res　52：529-540，1988

15) Satoh K, Yoshida H, Imaizumi T, et al : Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke　23：1090-1092，1992

16) Yamada Y, Yoshida H, Ichihara S, et al : Correlation between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis　150：209-216，2000

17) Dulioust A, Hilliquin P, Menkes CJ, et al : PAF-acether acetylhydrolase activity is increased in patients with rheumatoid diseases. Scand J Rheumatol　21：161-164，1992

18) Kirschbaum B : Platelet-activating factor acetylhydrolase activity in the urine of patients with renal diseases. Clin Chim Acta　199：139-146，1991

19) Karasawa K : Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Biochim Biophys Acta　1761：1359-1372，2006

20) Tetta C, Bussolino F, Modena V, et al : Release of platelet-activating factor in systemic lupus erythematosus. Int Arch Allergy Appl Immunol　91：244-256，1990

21) Claus RA, Russwurm S, Dohrn B, et al : Plasma platelet-activating factor acetylhydrolase activity in critically ill patients. Crit Care Med　33：1416-1419，2005

). Cardiovasc Drugs Ther　23：73-83，2009

23) Stafforini DM, McIntyre TM, Prescott SM : Platelet-activating factor acetylhydrolase from human plasma. Methods Enzymol　187：344-357，1990

24) Satoh K, Imaizumi T, Kawamura Y, et al : Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, HepG2．J Clin Invest　87：476-481，1991

25) Leach CA, Hickey DM, Ife RJ, et al : Lipoprotein-associated PLA2 inhibition―a novel, non-lipid lowering strategy for atherosclerosis therapy. Farmaco　56：45-50，2001

26) Chen CH : Platelet-activating factor acetylhydrolase : is it good or bad for you? Curr Opin Lipidol　15：337-341，2004

27) Karabina SA, Ninio E : Plasma PAF-acetylhydrolase : an unfulfilled promise? Biochim Biophys Acta　1761：1351-1358，2006

28) Fukuda Y, Kawashima H, Saito K, et al : Effect of human plasma-type platelet-activating factor acetylhydrolase in two anaphylactic shock models. Eur J Pharmacol　390：203-207，2000

29) Schuster DP, Metzler M, Opal S, et al : Recombinant platelet-activating factor acetylhydrolase to prevent acute respiratory distress syndrome and mortality in severe sepsis : phase IIb, multicenter, randomized placebo-controlled, clinical trial. Crit Care Med　31：1612-1619，2003

30) Opal S, Laterre PF, Abraham E, et al : Recombinant human platelet-activating factor acetylhydrolase for treatment of severe sepsis : results of a phase III, multicenter, randomized, double-blind, placebo-controlled, clinical trial. Crit Care Med　32：332-341，2004

31) Miwa M, Miyake T, Yamanaka T, et al : Characterization of serum platelet-activating factor (PAF) acetylhydrolase. Correlation between deficiency of serum PAF acetylhydrolase and respiratory symptoms in asthmatic children. J Clin Inves　82：1983-1991，1988

32) Stafforini DM, Satoh K, Atkinson DL, et al : Platelet-activating factor acetylhydrolase deficiency : a missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest　97：2784-2791，1996

33) Hiramoto M, Yoshida H, Imaizumi T, et al : A mutation in plasma platelet-activating factor acetylhydrolase (Val279→Phe) is a genetic risk factor for stroke. Stroke　28：2417-2420，1997

34) Yamada Y, Ichihara S, Fujimura T, et al : Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism　47：177-181，1998

35) Yoshida H, Imaizumi T, Fujimoto K, et al : A mutation in plasma platelet-activating factor acetylhydrolase (Val279Phe) is a genetic risk factor for cerebral hemorrhage but not for hypertension. Thromb Haemost　80：372-375，1998

36) 佐藤敬，高松滋，今泉忠淳，他：アテローム硬化．Initiating factorとしての内皮細胞障害．内皮細胞障害と血小板活性化因子(PAF)の産生．日本臨牀　46：552-557，1988

37) McIntyre TM, Prescott SM, Weyrich AS, et al : Cell-cell interactions : leukocyte-endothelial interactions. Curr Opin Hematol　10：150-158，2003

38) Unno N, Nakamura T, Kaneko H, et al : Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J Vasc Surg　32：263-267，2000

39) Stafforini DM, Numao T, Tsodikov A, et al : Deficiency of platelet-activating factor acetylhydrolase is a severity factor for asthma. J Clin Invest　103：989-997，1999

gene is associated with catalytic activities and cardiovascular disease in Korean men. J Clin Endocrinol Metab　91：3521-3527，2006

41) Blank ML, Lee T, Fitzgerald V, et al : A specific acetylhyrolase for 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (a hypotensive and platelet-activating lipid). J Biol Chem　256：175-178，1981

42) Stafforini DM, Prescott SM, McIntyre TM : Human plasma platelet-activating factor acetylhydrolase : purification and properties. J Biol Chem　262：4223-4230，1987

43) Kosaka T, Yamaguchi M, Miyanaga K, et al : Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin Chim Acta　312：179-183，2001

44) Saenger AK, Christenson RH : Stroke biomarkers : progress and challenges for diagnosis, prognosis, differentiation, and treatment. Clin Chem　56：21-33，2010

45) McIntyre TM, Prescott SM, Stafforini DM : The emerging roles of PAF acetylhydrolase. J Lipid Res　50：S255-S259，2009

/PAF acetylhydrolase. Circ Res　108：469-477，2011